Allogene Therapeutics Reports Trial Data

Allogene Therapeutics has released interim futility analysis data from its pivotal ALPHA3 trial for cemacabtagene ansegedleucel (cema-cel). The results show a 58.3% MRD clearance rate in the cema-cel arm compared to 16.7% in the observation arm for first-line treatment. This represents an absolute difference of 41.6%, exceeding the clinically meaningful benchmark of 25-30% MRD reduction based on literature. These findings suggest promising efficacy for cema-cel in treating certain hematologic malignancies.